Kairos Pharma Future Growth
Future criteria checks 0/6
Kairos Pharma's earnings are forecast to decline at 56.8% per annum. EPS is expected to decline by 24.1% per annum.
Key information
-56.8%
Earnings growth rate
-24.1%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -12 | -12 | -12 | 1 |
| 12/31/2025 | N/A | -3 | -3 | -3 | 1 |
| 12/31/2024 | N/A | -1 | -1 | -1 | 1 |
| 9/30/2024 | N/A | -3 | -2 | -2 | N/A |
| 6/30/2024 | N/A | -2 | 0 | 0 | N/A |
| 3/31/2024 | N/A | -2 | 0 | 0 | N/A |
| 12/31/2023 | N/A | -2 | 0 | 0 | N/A |
| 9/30/2023 | N/A | -1 | 0 | 0 | N/A |
| 6/30/2023 | N/A | -1 | 0 | 0 | N/A |
| 3/31/2023 | N/A | -1 | 0 | 0 | N/A |
| 12/31/2022 | N/A | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KAPA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KAPA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KAPA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if KAPA's revenue is forecast to grow faster than the US market.
High Growth Revenue: KAPA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KAPA's Return on Equity is forecast to be high in 3 years time